Navigating Manufacturers Through the Political Sea of Healthcare
Guiding drug manufacturers through the tumultuous waters of healthcare policy has never been more important. Those harbor pilots of policy and the potential financial ramifications come in the form of economists and legislative experts. Despite initial Republican interest in repealing and replacing the Affordable Care Act (ACA), Congress ultimately decided to modify the Act, eliminating certain benefits such as cost-sharing subsidies that payers depend on and that helped subsidize out-of-pocket expenses for low-income patients.
For the full article, check out FiercePharma.